Biomedical Science and Research Journals | Zoledronic Acid and the Mevalonate Pathway: An Opportunity to Overcome Resistance in Hormonal HER2 positive Breast Cancer
Zoledronic Acid and the Mevalonate Pathway: An Opportunity to Overcome Resistance in Hormonal HER2 positive Breast Cancer
The Human Epidermal growth factor Receptor-type2 (HER2) positive breast characteristics and treatment
The HER2 positive breast cancer subtype exhibits a distinct
behaviour from the others, usually accompanied with early relapse,
including a higher percentage of brain metastasis [1]. Therefore,
it remains a challenge in clinical practice [2]. On the other hand,
anti-HER2 target therapy has dramatically changed the course of
the disease [3]. In neoadjuvant, adjuvant and metastatic setting,
the advent of trastuzumabe and pertuzumab, both monoclonal
antibody which binds to HER2 receptor in different domains
on tumoral cells inhibiting it progression synergistically with
cytotoxic chemotherapy, has improved several endpoints such as
pathological complete response rate, relapse-free, progressionfree
and overall survival [4]. Beyond trastuzumab and pertuzumab
combination, an antibody– drug conjugate (ADC) like trastuzumab
emtansine (T-DM1) and an irreversible pan-HER tyrosine kinase
inhibitor (TKI) such as neratinib meliorated the previous endpoints
[5,6]. However, many patients still develop disease recurrence or
progressive disease and die.
The current effort from scientists and clinicians is improve the
results of anti-HER therapy and mainly it’s resistance [7]. There
is a bidirectional crosstalk between HER2 and estrogen pathway
[8]. Anti-HER2 targeting can up-regulate estrogen pathways
and additionally estrogen pathway activation can reduce anti-
HER2 activity [9]. Differences in responses are expected to occur
depending on the positivity of hormonal receptors, justifying
humbled performances of HR-positive subtype when compared to
HR- negative in terms of pathological response rate in clinical trials
as shown by Schedin 2018. Strategies to overcome resistance in
HER2- positive breast cancer includes TKIs [10], and combinations
of anti-HER2 therapy with other agents like immune checkpoint
inhibitors [11], CDK4/6 inhibitors [12], and PI3K/AKT/mTOR
inhibitors [13]. While the raise of cyclin inhibitors in pre-clinical
models seems to be promising [14] and several studies are ongoing,
other attempts has generally failed in demonstrating improvements
such as standard therapy combination with hormonal agents in
neoadjuvant setting [15].
Crosstalk’s between HER2 and Mevalonate Pathway
Pre-clinical evidence revealed the previously unknown crosstalk between the estrogen, HER2, Notch and the mevalonate pathway [18]. HER2 protein initiates a cascade of phosphorylation’s when activated [19]. Then interaction between core promotion and maintaining cell survival pathways occurs [20], such as the mitogen-activated RAS-RAF-protein kinase (MAPK)/extracellular signal- regulated kinase (MEK)-ERK and the phosphoinositide 3-kinase (PI3K)-PTEN-AKT, as schematic shown by in the figure 1 from Goltsov et al 2018 paper [21].Zoledronic Acid Combination and the Its Potential Benefits
Zoledronic acid (ZOL) is a bisphosphonate which promotes clinical benefits in breast cancer [22,23]. In preclinical scenario, it demonstrated apoptotic, anti- proliferation [24] and antiangiogenic effect [25], reduction of invasion and cell migration [26], immunogenic effect [27] and act synergistically with chemotherapy [28,29]. When the farnesyl pyrophosphate synthetize activity is inhibited by ZOL affecting the mevalonate metabolism, a GTPases proteins prenylation do not occurs, interfering with RAS activity, resulting in a potential anti-tumoral activity [30]. The Zo-NAnTax trial [31], is a proof of concept phase II study that explores this potential therapeutic benefit based on drug repositioning [32] from our group. HER2-positive locally advanced breast cancer patients were treated with four cycles of anthracycline/cyclophosphamide (AC) plus zoledronic acid (ZOL), followed by four cycles of docetaxel with trastuzumab plus ZOL (ACZOLx4 > THZOLx4) pre- operatively. The primary endpoint in this trial was pathologic complete response (pCR) and most relevantly the secondary molecular end-points might potentially translate this pre-clinical into clinical evidence. The study was finished however results are to be published.Conclusion
HER2-positive breast cancer treatment is a challenge,
however the crosstalk between the estrogen, HER2, Notch and
the mevalonate pathways represents a window of opportunity to
improve resistance in this subset of tumours.
To view fulltext of article:https://biomedgrid.com/fulltext/volume2/zoledronic-acid-and-the-mevalonate-pathway.000618.php
For More information: biomedical open access Journals: https://biomedgrid.com/index.p
For More information: biomedical open access Journals: https://biomedgrid.com/index.p
Biomedical Science and Research
Know More Information: Biomed Grid Please Click on : https://biomedgrid.com
If you have Herpes in your whole body such as fever blisters, hsv, or roofing shingles you know what it is like to stay with the pain and discomfort that herpes delivers. I don't need to tell you how awesome it would be to find something that works so that you no longer need to fear about stress or outbreak,Dr Itua herbal medicine cure my herpes in two weeks of taking is genuine and natural herbal medicine it has no side effect, The reason I'm writing this is that I promised Dr Itua I will share his herbal work to the world to see Herpes is no more a big deal.also Dr Itua can as well cure the following diseases...HIV,Hsv 1/2,Hepatitis B,Breast Cancer, Cervical Cancer,Leukemia Cancer,Lung Cancer,Brain CANCER,Blood Cancer,Prostate Cancer,Diabetes, Men/Woman Infertility, Scoliosis,Fibromyalgia,Fluoroquinolone ToxicitySyndrome Fibrodysplasia Ossificans Progressiva.Fatal Familial Insomnia Factor V Leiden Mutation , Lottery Spell,Copd, Shingles,Fibroid, Fibromyalgia, Liver/Kidney Inflammatory, Epilepsy,Hpv,Weak Erection,Wart Remover,Cold Sore, Coeliac disease,Creutzfeldt–Jakob disease,Cerebral Amyloid Angiopathy, Glaucoma.Lupus, Lyme Disease,, Cataracts,Macular degeneration,Cardiovascular disease,Lung disease.Enlarged prostate,Osteoporosis.Alzheimer's disease,Dementia.Ataxia,Arthritis,Amyotrophic Lateral Sclerosis,Alzheimer's disease,Adrenocortical carcinoma.Asthma,Allergic Asthma. Here His Contact...drituaherbalcenter@gmail.com/ . Whatsapp Phone.+2348149277976. I paid for his herbal medicine and sent it to me through Courier Service which I pick it urgently and used.
ReplyDelete